Antwerp (BE), Munich & Heidelberg (D), 20 January 2026– European investment company Gimv, together with EQT Life Sciences as co-lead investor, is pleased to announce the successful completion of a €51 million ($59 million) Series B financing round for Exciva GmbH (www.exciva.com), a Heidelberg-based biopharmaceutical company developing novel therapies for neuropsychiatric conditions. Additional investors participating in the round include Fountain Healthcare Partners, LifeArc, Modi VC, and Carma Fund, alongside existing investor Andera Partners.
